



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7044

Title: TNF Inhibitors to Treat Ulcerative Colitis in a Metastatic Breast Cancer Patient

Reviewer code: 01221849

Science editor: Qi, Yuan

Date sent for review: 2013-11-02 20:14

Date reviewed: 2013-11-06 18:13

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

I think that the present study entitled "TNF Inhibitors to Treat Ulcerative Colitis in a Metastatic Breast Cancer Patient. A Case report and Literature Review" provides an interesting point to gastroenterologists. However, there is a defect and an inadequate description in the Discussion section. Authors presented a 54-year-old female patient with metastatic breast cancer and ulcerative colitis (UC) who was treated with ADA. She has received a series of combination chemotherapy with concomitant adalimumab treatments for ulcerative colitis, finally leading to not only an elimination of recurrent breast cancer but also a complete remission of ulcerative colitis. Authors concluded that it is possible to successfully treat an advanced cancer like metastatic BC despite concomitant TNF- α inhibitor therapy Major 1. Authors stated that 'a TNF- α inhibitor acted in fact as an anti-neoplastic agent' in page 8, line 20 to 21. This deception is a problem. The present report showed no evidence that adalimumab directly eliminated recurrent breast cancer. A series of combination chemotherapy achieved and eliminated recurrent breast cancer. Thus, it is not like that adalimumab deteriorates breast cancer, and that there is association between elimination of breast cancer adalimumab treatment. It is difficult and unnatural to think that adalimumab acts as an anti-neoplastic agent. Actually adalimumab has not currently been approved as an anti-neoplastic agent in the world wide. Please delete and improve the description that a TNF- α inhibitor acted in fact as an anti-neoplastic agent



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7044

Title: TNF Inhibitors to Treat Ulcerative Colitis in a Metastatic Breast Cancer Patient

Reviewer code: 02530755

Science editor: Qi, Yuan

Date sent for review: 2013-11-02 20:14

Date reviewed: 2013-11-10 17:35

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This is an intriguing case-report. Is is properly described and discussed. I have no major or minor issues to raise



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 7044

Title: TNF Inhibitors to Treat Ulcerative Colitis in a Metastatic Breast Cancer Patient

Reviewer code: 02462488

Science editor: Qi, Yuan

Date sent for review: 2013-11-02 20:14

Date reviewed: 2013-11-11 11:08

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Very interesting case report given that this situation occurs often. Only comment would be that it is difficult to claim that anti-TNF has anti-neoplastic effect because 3 year is a short follow up and longer follow up data is required.